Cyclosporin treatment for relapse and resistant Nephrotic Syndrome in adult

Main Article Content

Artit Indranoi

Abstract

Nephrotic syndrome is common kidney disease. It was found that the recurrence rate was 50-60% after discontinuation of the drug within 1 year. Post-relapse treatment involves steroids and various immunosuppressants such as Cyclosporin to maintain disease remission. Evidence base study of relapse nephrotic syndrome in Thai adults was limited. Retrospective descriptive analysis from medical records associated with relapse and resistant nephrotic syndrome in adults over 15 years who received Cyclosporin was conducted to compare the efficacy of Cyclosporin in between complete remission and partial remission groups for significant factors affecting response and dosage. 64 patients with relapse and resistant nephrotic syndrome received Cyclosporin and were enrolled, mean age of 41.3 years (15-70 years). The response rate of Cyclosporin treatment at 12 weeks was 38 complete remissions (59.4%), and 26 partial remissions (40.6%) with a mean cyclosporin dose of 110.94 ± 43.1 mg/day (1.72 ± 0.68 mg/kg/day) in combination with a mean Diltiazem dose of 103.13 ± 59 mg/day. Factors affecting poor response to Cyclosporin were microscopic hematuria and urinary protein to creatinine ratio greater than 8. Cyclosporin has good efficacy for relapse and resistant nephrotic syndrome without serious side effects.

Downloads

Download data is not yet available.

Article Details

How to Cite
Indranoi, A. (2022). Cyclosporin treatment for relapse and resistant Nephrotic Syndrome in adult. Journal of Medical and Public Health Region 4, 12(2), 71–81. Retrieved from https://he01.tci-thaijo.org/index.php/JMPH4/article/view/258028
Section
Original Articles

References

Hull RP, Goldsmith DJA. Nephrotic syndrome in adults. BMJ 2008;336:1185-9.

วสันต์ สุเมธกุล. Patients with Nephrotic Syndrome [Internet]. [cited 2013 February 25]. Available from: https://med.mahidol.ac.th/med/sites/default/files/public/pdf/medicinebook1/Patients%20with%20Nephrotic%20Syndrome.pdf.

Floege J, Rovin BH, Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S): S1-S276.

Sumboonnanonda A, Touphaythoune K, Mongkonsuk W. Longterm Renal Outcome of Idiopathic Nephrotic Syndrome in Children. Siriraj Med J 2016;68:363-8.

Sumboonnanonda A, Chongchate N, Suntornpoch V, Pattaragarn A, Supavekin S. Difficult-to-Treat Nephrotic Syndrome: Management and Outcome. J Med Assoc Thai 2005; 88(Suppl 8): S142-8.

Cattran DC, Alexopoulos E, Heering P, Hoyer PF, Johnston A, Meyrier A, et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: Workshop recommendations. Kidney Int 2007;72,1429–47.

Ponticelli C, Passerini P. The place of cyclosporine in the management of the primary nephrotic syndrome. Biodrugs 1999;12:327–41.

Laopornpichayanuwat S. Nephrotic Syndrome in Thai Children: Nakornping Hospital Experience. Siriraj Med J 2006;58:648-53.

Rivera F, López-Gómez JM, Pérez-García R. Clinicopathologic correlations of renal pathology in Spain. Kidney Int 2004;66(3):898-904.

Dem PV, Huong NT, Thuy Lien NT, Kien NT, Nam TT, Quynh Huong NT. Outcomes of Cyclosporine A Treatment in Children with Steroid Resistant Nephrotic Syndrome at Vietnam National Children’s Hospital. ĐHQGHN: Khoa học Y Dược 2018;34(1),107-13.

Zhang Z, Wu P, Zhang J, Wang S, Zhang G. The effect of statins on microalbuminuria, proteinuria, progression of kidney function, and all-cause mortality in patients with non-end stage chronic kidney disease: A meta-analysis. Pharmacol Res 2016;105:74-83.

Waldman M, Crew RJ, Valeri A, Busch J, Stokes B, Markowitz G, et al. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol 2007;2(3):445-53.

Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, et al. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. N Engl J Med. 2019;381(1):36-46.

Kurathong P, Jesdapatarakul S. Long-term follow-up study of IgM associated nephrotic syndrome patients: clinical outcome and prognostic indicators. J Med Assoc Thai 2000;83(3):315-24.

Argolini LM, Frontini G, Elefante E, Saccon F, Binda V, Tani C, et al. Multicentric study comparing cyclosporine, mycophenolate mofetil and azathioprine in the maintenance therapy of lupus nephritis: 8 years follow up. J Nephrol 2021;34(2):389–98.

Matsumoto H, Nakao T, Okada T, Nagaoka Y, Shino T, Yoshino M, et al. Initial remission-inducing effect of very low-dose cyclosporin monotherapy for minimal-change nephrotic syndrome in Japanese adults. Clin Nephrol 2001;55:143–8.

Mezzano S, Flores C, Ardiles L, Foradori A, Elberg A. Study of neoral kinetics in adult renal transplantation treated with diltiazem. Transplant Proc 1998;30(5):1660-2.